Partnership designed to expand QIAGEN’s leadership in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for can...
MedX Health Corp. , a global leader in teledermatology, is pleased to announce a strategic collaboration in the Italian healthcare market between Vitamed...
Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline ...
Acquisition adds Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases Strengthens QIAGEN Digital Insigh...
Worldwide first artificial Human Platelet Lysate (HPL) solution – a key ingredient for the research & production of cell-based pharmaceutical...
600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pa...
Symbiosis Pharmaceutical Services (Symbiosis), a global biopharmaceutical Contract Manufacturing Organisation (CMO) specialising in the sterile fill fi...
Exclusive licensing and R&D collaboration accelerate the development of a novel gene vector platform for precision gene therapy in Hepatocellular Car...
Total revenues remain strong at CHF 7.2 billion (CHF 7.3 billion in 2023) Record CHF 833 million raised by privately funded companies drives 22%...
Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, announces today a new organizati...
Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic...
In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of d...
Bavarian Nordic A/S announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Ki...
Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE®...
© 2025 Biopharma Boardroom. All Rights Reserved.
